Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ: ADAP )

0.5780 +0.0015 (+0.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Adaptimmune Reports Q1 2024 Financial and Business Updates
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date... 
Via Newsfile
Exposures Product Safety
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adaptimmune Therapeutics Earnings Preview
Via Benzinga
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader... 
Via Newsfile
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. 
Via Benzinga
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date... 
Via Newsfile
Topics Economy
Exposures Product Safety Supply Chain
Earnings Scheduled For March 6, 2024
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
Via Benzinga
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for... 
Via Newsfile
Exposures Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be... 
Via Newsfile
Exposures Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better... 
Via Newsfile
Exposures Product Safety
Adaptimmune Receives Transfer of IND for Lete-cel Program
Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma... 
Via Newsfile
Adaptimmune Reports Third Quarter Financial Results and Business Update
Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission... 
Via Newsfile
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen... 
Via Newsfile
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response... 
Via Newsfile
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had... 
Via Newsfile
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in... 
Via Newsfile
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across... 
Via Newsfile
Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces... 
Via Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.